EyeGate Pharmaceuticals Inc. appointed Steven Boyd to its board.

Boyd is the chief investment officer of Armistice Capital, a New York-based equity hedge fund focused on the healthcare and consumer sectors.

Waltham, Mass.-based EyeGate is a clinical-stage specialty pharmaceutical company developing therapies to treat eye-related diseases and disorders.